CI

At a glance

ClinicalIndex Comparison Record
Phase 2Recruiting· 20 target
Drug / intervention
CM336 Injectiondrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06799611
NCT06799611Phase 2RecruitingMonitorUpdated 15mo ago · Completion was 4mo ago
Slow Enrollment
Monitor
CompareCT.gov

An Open, Exploratory Clinical Study to Assess Safety and Efficacy of BCMA-CD3 Bispecific Antibody CM336 in the Treatment of Primary Immune Thrombocytopenia

Institute of Hematology & Blood Diseases Hospital, China·interventional·Posted Jan 29, 2025·Updated Mar 13, 2025

In Brief

A Phase 2 clinical trial evaluating CM336 Injection for Immune Thrombocytopenia (ITP) and Treatment. Currently recruiting, targeting 20 participants across 1 site.

Signals

Enrolling slower than its timeline implies

Detailed Summary

To evaluate the efficacy and safety of CM336 in the treatment of refractory adult primary immune thrombocytopenia

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsImmune Thrombocytopenia (ITP), Treatment
CountriesChina
Collaborators--

Timeline

Phase 2Recruiting
202520262027
First PostedJan 29, 2025
Enrollment StartMar 3, 2025
Primary CompletionJan 31, 2026
Study CompletionJan 31, 2027
TodayJul 1, 2026
Enrollment to primary: 11 monthsPosted 1.4 years ago

Interventions

CM336 Injectiondrug

subcutaneous CM336 administration step-up dosing Dose and frequency of CM336 according to the protocol